好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Subjective and Objective Measures of Cognitive Function are Correlated in Persons with Post-COVID-19 Condition: A Secondary Analysis of a Randomized Controlled Trial
Infectious Disease
P1 - Poster Session 1 (11:45 AM-12:45 PM)
10-009

We sought to determine the association between subjective and objective cognitive functions in a well-characterized cohort of adults aged 18 to 65 who meet the World Health Organization (WHO) criteria for post-COVID-19 condition (PCC)

It is unclear whether subjective and objective measures of cognitive function in PCC are correlated. Individuals with PCC frequently report subjective cognitive issues as their primary concern during clinical visits. However, the degree to which these subjective complaints correlate with objective cognitive function remains insufficiently characterized. The extent of this correlation has mechanistic and clinical implications.

This post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial includes baseline data on subjective and objective measures of cognition in a rigorously characterized cohort living with PCC. We evaluated the association between subjective and objective cognitive function, as measured by the Perceived Deficits Questionnaire, 20-item (PDQ-20), and the Digit Symbol Substitution Test (DSST) and Trails Making Test (TMT)-A/B, respectively.

A total of 152 participants comprised the baseline sample. Due to missing data, our statistical analyses included 150 for self-reported PDQ-20, 147 for combined DSST-measured cognitive function  (composite z-score of the Pen/Paper plus Online CogState Version, NcombinedDSST), 71 for in-person DSST (Pen/Paper Version), and 70 each for TMT-A and TMT-B measured cognitive function. After adjusting for age, sex, and education, the PDQ-20 was significantly correlated with the pen-and-paper DSST (β = -0.003, p = 0.002) and TMT-B (β = 0.003, p = 0.008) scores, but not with TMT-A scores (β = -0.001, p = 0.751).

Overall, a statistically significant correlation was observed between subjective and objective cognitive functions. Clinicians providing care for individuals with PCC who report subjective cognitive complaints may consider taking a measurement-based approach to cognition at the point of care, focusing exclusively on patient-reported measures.

Authors/Disclosures
Moiz Lakhani, BHSc, MD (C)
PRESENTER
Mr. Lakhani has nothing to disclose.
Angela T. Kwan, MSc Miss Kwan has nothing to disclose.
Kayla Teopiz Kayla Teopiz has received personal compensation in the range of $10,000-$49,999 for serving as a Contractor with Braxia Scientific Corp. Kayla Teopiz has received personal compensation in the range of $500-$4,999 for serving as a Contractor with Brain and Cognition Discovery Foundation.
Charnjit S. Nijjar, MD Candidate Mr. Nijjar has nothing to disclose.
Shakila Meshkat, MD Dr. Meshkat has nothing to disclose.
Sebastian Badulescu Sebastian Badulescu has nothing to disclose.
Ho C. Man, MD Prof. Man has nothing to disclose.
Greg Rhee, PhD Prof. Rhee has nothing to disclose.
Hartej Gill, PhD Mr. Gill has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck.
Roger McIntyre Roger McIntyre has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, Atai Life Sciences. Roger McIntyre has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, Atai Life Sciences. Roger McIntyre has received personal compensation in the range of $5,000-$9,999 for serving as a Research Grant Support with CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute.